Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India.
| Revenue (TTM) | $331.19B |
| Gross Profit (TTM) | $166.18B |
| EBITDA | $54.67B |
| Operating Margin | 4.25% |
| Return on Equity | 8.84% |
| Return on Assets | 4.01% |
| Revenue/Share (TTM) | $66.41 |
| Book Value | $0.81 |
| Price-to-Book | 2.54 |
| Price-to-Sales (TTM) | 0.03 |
| EV/Revenue | 2.995 |
| EV/EBITDA | 14.88 |
| Quarterly Earnings Growth (YoY) | -68.70% |
| Quarterly Revenue Growth (YoY) | -5.60% |
| Shares Outstanding | $833.00M |
| Float | $3.59B |
| % Insiders | 0.00% |
| % Institutions | 15.85% |
Volatility is currently contracting
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bridion--Dr. Reddy's Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, in the United States.
Investigation focuses on RDY losses after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches and shares fell approximately 9%. NEW YORK, July 31, 2026 /PRNewswire/ -- On July 22, 2026, Dr. Reddy's Laboratories (NYSE: RDY) shares fell approximately 9% after the Company reported a Q1 FY27 earnings miss and disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches.
RDY shares fell approximately 9% after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches. The investigation focuses on the Company's regulatory statements about semaglutide filings and patient safety. RDY shares fell approximately 9% after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches. The investigation focuses on the Company's regulatory statements about semaglutide filings and patient safety.
RDY shares fell approximately 9% after Q1 FY27 results showed a 5.66% year-over-year revenue decline and a 68.7% profit decline. The investigation focuses on investor losses tied to the market reaction to the earnings miss.
In this CNBC exclusive, Dr. Reddy's Laboratories CEO Erez Israeli breaks down the company's recent Q1 earnings report. He addresses the temporary halt in Semaglutide production due to an impurity issue and weighs in on Trump administration's vow to increase generic drug import tariffs to 100% by 2030.
U.S. President Donald Trump's plan to impose tariffs on generic drugs will lead to patients in the U.S. paying higher prices, warned the CEO of Indian pharmaceutical company Dr Reddy's. Manufacturing of generic drugs in India leads to a significant decrease in the cost of medicine to the United States.
RDY's fiscal Q1 earnings and revenues miss estimates as weaker North America generics sales hurt results, sending shares down 9%.
Dr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call Transcript
Dr. Reddy's Laboratories NYSE: RDY reported a year-over-year revenue decline and sharply lower profitability for the first quarter of fiscal 2027, as lower lenalidomide sales and semaglutide API-related challenges weighed on results. Management said the company's base business, excluding lenalidomide, continued to grow at a double-digit rate across key geographies.
Indian drugmaker Dr Reddy's reported a smaller-than-expected quarterly profit on Wednesday, as muted sales of a key generic oncology drug and pricing pressure weighed on the competitive U.S. market.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RDY and any ticker you trade — then tracks every position and per-strategy win rate.
